Purchase this article with an account.
F. Boscia, R. Dammacco, G. Quaranta, T. Micelli Ferrari, C. Sborgia; Intravitreal Triamcinolone Acetonide for Treatment of Patients with Irvine-Gass Sindrome . Invest. Ophthalmol. Vis. Sci. 2003;44(13):4925.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To investigate if intravitreal injection of triamcinolone acetonide (TA) is safe and effective in treating cystoid macular edema (CME) secondary to Irvine-Gass syndrome, unresponsive to others forms of therapy. Methods: A prospective nonrandomized pilot study including 5 patients (6 eyes) with Irvine-Gass syndrome, cronic CME, (> 6 months) and visual acuity ≤ 20/50, resistant to conventional medical therapy, was carried out. All patients were injected with 4 mg (0.1 ml) of TA using a 27 gauge needle, through the inferior pars plana, 3,5 mm from the corneal limbus.Baseline examination and investigations were performed at 1, 3 and 6 months after enrollment, including best-corrected visual acuity (VA), fundus photography and fluorescein angiography (FA), measurements of intraocular pressure and of retinal thickness with optical coherence tomography (OCT). Results: After a follow-up of 6 months, best corrected VA improved in 5 eyes, stabilized in one eye. Central macular thickness decreased in all patients. No intraoperative complications were observed. Postoperative complications consisted only in an increased intraocular pressure to 25 mmHg and in one case of pseudoipopion ,which required medical treatment. Reinjection of TA was performed in 2 eyes after 3 months because of recurrence of macular edema. Conclusions: Intravitreal TA is a promising therapeutic method for cronic CME that fails to respond to conventional therapy. Complications do not appear to be prohibitive. Further study is warranted to assess the long-term efficacy and safety, and the need for retreatment.
This PDF is available to Subscribers Only